Abstract library

507 results for "Le Large".
#151 Rationale for combining mTOR with other targeted agents in the treatment of neuroendocrine tumors
Introduction: Advanced neuroendocrine tumors (NETs) are aggressive and incurable with standard treatment. Many cellular targets are being evaluated in this patient population, including mammalian target of rapamycin (mTOR), a kinase that is the central regulator of several signaling pathways related to cell growth, angiogenesis, and bioenergetics. Because mTOR serves as a neoplastic switch activated by many cancer-related mutations, mTOR inhibition may have broad efficacy across tumor types, including NETs. Somatostatin analogs (SSAs) have long been used to treat carcinoid symptoms in NET patients. The SSA octreotide long-acting release (LAR) demonstrated significant antitumor effects against advanced midgut NETs in the phase III PROMID study.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Kjell Öberg
Authors:
#1240 Targeted Therapies as First Line Option in Very Advanced Unresectable Pancreatic Neuroendocrine Tumors
Introduction: Neuroendocrine tumors are an entity of rare, heterogeneous group of tumors that can arise from different sites within the body. Although number of different treatment types and modalities exist, chemotherapy remains as the first line option in the management of advance pancreatic NETS (pNETS); two targeted therapies, sunitinib and everolimus remains available only for second line and beyond in Canada.
Conference: 12th Annual ENETS Conference (2015)
Category: Clinical cases/reports
Presenting Author: MD Young Soo Rho
Authors:
#624 Identification of New GPCR Targets in NET Cell Lines Using Ligand Screening
Introduction: Although somatostatin analogs constitute an important part of current therapeutic strategies, both hypersecretion and proliferation of NETs cannot be controlled efficiently in many patients. Identifying and dissecting new molecular targets and regulatory pathways may help to improve diagnostic and therapeutic options for NET patients.
Conference: 10th Annual ENETS Conference (2013)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Dr. Carsten Grötzinger
Authors:
#675 Olfactory Receptor 51E1 is a Potential Novel Target for Diagnosis and Treatment of Somatostatin Receptor Negative Lung Carcinoid Patients
Introduction: Somatostatin receptor (SSTR) expression may be used for diagnosis and therapy of lung carcinoids. However, novel targets are requested.
Conference: 10th Annual ENETS Conference (2013)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Tao Cui
Authors:
#939 Large Cell Neuroendocrine Carcinoma of the Gallbladder: A Case Report and Literature Review
Introduction: Primary large cell neuroendocrine carcinoma (LCNEC) of the gallbladder is rare. The standard treatment for gallbladder NEC with liver metastases has not been established, but combination chemotherapy with etoposide plus cisplatin (EP) is recommended for NEC patients with liver metastasis, regardless of the primary tumor site.
Conference: 11th Annual ENETS Conference (2014)
Category: Clinical cases/reports
Presenting Author: MD Shoichi Nakazuru
Authors:
#1065 Functional Role of miR-196a in Neuroendocrine Tumor Cells
Introduction: An exclusive miRNA profiling of small intestinal neuroendocrine tumors (SI-NETs) was published in 2013; and nine miRNAs were selected for further investigations. We chose miR-196a to elucidate its target genes and biological functions, by using NET cells as in vitro models.
Conference: 12th Annual ENETS Conference (2015)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: Hao Shi
Authors:
#2018 Ex Vivo Activity of Cytotoxic Drugs and Targeted Agents in Small Intestinal Neuroendocrine Tumors
Introduction: Small Intestinal Neuroendocrine Tumours (SI-NETs) are considered to be generally resistant to systemic treatment. To date predictive markers for drug activity are lacking.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Kosmas Daskalakis
Authors:
#1775 Potential Therapeutic Targets for Gastric Poorly Differentiated Neuroendocrine Carcinoma
Introduction: Gastric poorly differentiated neuroendocrine carcinoma (G-PDNEC) is rare and aggressive. Patients often present with distant metastases at initial diagnosis.
Conference: 14th Annual ENETS conference (2017)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: PROF. Yuan Ji
Authors:
#2123 Large Cell Neuroendocrine Carcinoma (LCNEC) Associated with a Dysplastic Sessile Serrated Lesion (SSL) and Deficient Mismatch Repair (MMR) Protein: A Case Report.
Introduction: Colorectal poorly differentiated neuroendocrine carcinomas (NECs) are rare, but extremely aggressive. The mechanisms of their carcinogenesis and aggressiveness are still largely unknown. Recently Nobuyoshi Takizawa showed that the molecular features of colorectal NECs are similar to those of adenocarcinoma and not to those of NETs and they were more evident in small cell NECs than in large cell NECs. This is supported by combined cases with conventional adenoma/adenocarcinoma and NECs. Stelow et al showed that DNA mismatch repair proteins were intact in 14/15 colorectal small cell NECs. Two cases of LCNECs arising from SSL have been reported so far in the literature.
Conference: 15th Annual ENETS conference (2018)
Category: Case reports
Presenting Author: Dr Tu Vinh Luong
Authors:
#2210 213 Bi and Ac 225 DOTATOC Receptor Labeled Targeted Alpha-Radionuclide Therapy in Neuroendocrine Tumors Refractory to Beta Radiation - Early Experience
Introduction: Radiopeptide therapy using a somatostatin analogue labeled with alpha emitters Actinium 225 and Bismuth 213 DOTATOC is a novel therapeutic option in metastatic neuroendocrine tumors (NET), with few alternative therapeutic options for patients with beta refractory disease. We report the first experience with 213Bi and Ac225 DOTATOC targeted alpha therapy (TAT) in treatment of well differentiated metastatic NETs at a tertiary care hospital in India.
Conference: 15th Annual ENETS conference (2018)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Dr Sugandha Dureja
Authors: